In-depth articles on peptide science, regulatory compliance, and research developments — for patients, researchers, and healthcare professionals.
Medical Disclaimer: Articles on this site are for informational purposes only and do not constitute medical advice. Consult a licensed healthcare provider before using any peptide or supplement.
Skin is the most evidence-rich application area for peptide therapy. This guide covers oral collagen peptides (human RCT data), GHK-Cu copper peptide (wound healing and skin remodeling), topical cosmetic peptides, and what medical-grade approaches can realistically deliver.
From thymosin alpha-1 — approved for clinical use in over 35 countries — to KPV's gut immune axis effects and GLP-1's documented anti-inflammatory outcomes, this guide organizes the immune-relevant peptide landscape by evidence tier and clinical context.
How do you build an actual anti-aging peptide approach? This guide organizes longevity peptides by evidence tier and goal, covers monitoring requirements, and explains what these protocols can — and cannot — realistically deliver.
Beyond weight loss and diabetes: semaglutide and its predecessors are being studied for Parkinson's disease, Alzheimer's prevention, alcohol use disorder, and cognitive function. Here's what the clinical trial data actually shows — and where the evidence is still early.
SURMOUNT-4 and STEP 4 trial data show that most patients regain significant weight after stopping semaglutide or tirzepatide. Here's what the science shows about why regain happens, how fast it occurs, and what strategies can help maintain results.
A certificate of analysis is not the same as pharmaceutical quality. This guide explains what COAs actually measure, what endotoxin testing means for injectable safety, how 503A/503B compounding differs from research chemical vendors, and the specific red flags that matter.
From selank's anxiolytic effects to GLP-1's Parkinson's trials, several peptides have documented interactions with brain chemistry. This guide organizes the cognitive peptide landscape by evidence tier, mechanism, and intended use.
BPC-157 was originally discovered as a gastric cytoprotective compound. Here's a thorough look at what the preclinical evidence shows for IBD, NSAID-induced gut damage, leaky gut, and the gut-brain axis — and what it doesn't show.
BPC-157, TB-500, collagen peptides, GH secretagogues — which peptides have preclinical or clinical evidence for injury recovery, and how does that evidence map to tendons, ligaments, muscle, bone, and cartilage? A research-forward guide.
From FDA-approved GLP-1 agonists to AOD-9604's Phase 3 trials to GH secretagogues for body composition — a clear-eyed look at which peptides have genuine evidence for weight-related outcomes, which are promising but unproven, and which don't have evidence at all.
A guide to how peptides are being researched for men's health concerns — from growth hormone decline and body composition to sexual function and recovery. What the evidence shows and what it doesn't.
Head-to-head trial data, five-year cardiovascular outcomes, kidney protection, heart failure, weight regain after stopping, and a new eye safety signal — here's what the 2024–2026 research cycle has changed about how to think about GLP-1 therapy.
The global peptide therapeutics market has hit $40–50 billion. Compounding access has narrowed sharply. A research chemical gray market is growing. Here's how to read the industry landscape as an informed consumer.
From a triple GLP-1/GIP/glucagon agonist outperforming everything before it to the first oral semaglutide Parkinson's trial and a BPC-157 analog in humans — here's what's moving through clinical development and why it matters.
Studies show 25–40% of weight lost on semaglutide and tirzepatide comes from lean mass, not fat. Here's what the research says about why this happens, how much it matters, and what you can actually do — including the peptide therapies being investigated.
Most peptide therapy patients eventually combine more than one peptide. Here's how experienced clinicians think about combination rationale, sequencing, monitoring, and the combinations that warrant extra caution.
Sarcopenia affects up to half of adults over 70 and is the single greatest modifiable risk factor for loss of independence. Here's what the evidence says about GH secretagogues, GLP-1 and muscle loss, collagen peptides, and the safety considerations specific to older adults.
From the only FDA-approved peptide for female sexual dysfunction to research on hypothalamic amenorrhea, perimenopause, and body composition — here's what the evidence says about peptides and women's health specifically.
AOD-9604 is a GH fragment peptide that went further through formal drug development than almost any compounded peptide — including three Phase 3 trials that did not achieve their primary endpoints. This guide covers the mechanism, the complete clinical history, why the trials failed, what the GRAS status actually means, the injectable vs. oral distinction, and what patients need to know about gray-market Fragment 176-191 products.
A 2026 review documents BPC-157's pain-reducing effects across multiple animal models via mechanisms distinct from NSAIDs and opioids. This guide covers the analgesic mechanisms in depth — opioid sensitivity modulation, dopaminergic effects, NO pathway interactions, NSAID comparison — and explains why the oral vs. injectable route question is unusually important for this specific peptide.
GHK-Cu is the only peptide with both a 50-year research history and widespread cosmetic use. Here's what the science actually supports — for topical use, for hair, for wound healing, and for the emerging injectable question.
GLP-1 medications reduce hunger effectively but have inconsistent effects on reward-driven eating. A 2026 review in Obesity Science & Practice examines why combining semaglutide or tirzepatide with naltrexone/bupropion may address both pathways — and what patients who plateau need to understand about the biology.
Peptide therapy covers dozens of compounds with very different evidence bases, approved uses, and risk profiles. This guide helps you figure out whether there is a peptide approach relevant to your situation — and what questions to bring to a doctor before starting anything.
Monitoring is not optional on peptide therapy — it catches problems early, confirms the therapy is working, and protects you if something changes. This guide covers what to measure, when, and why for GLP-1 drugs, GH secretagogues, PT-141, and other commonly used peptides.
GH secretagogues, BPC-157, and other peptides are widely used in fitness and athletic communities. A 2026 critical review found the evidence base is far thinner than the marketing suggests — and the risks more serious. Here is what performance-oriented users need to know.
A landmark 2026 Nature study of nearly 28,000 patients identified genetic variants in GLP1R and GIPR that predict both weight loss response and nausea risk from semaglutide and tirzepatide. Here is what the science means, how receptor genetics shape drug response, and what patients can realistically do with this information today.
MOTS-c is a peptide encoded in mitochondrial DNA — the first of its kind found to act as a systemic metabolic signal. KPV is a three-amino acid anti-inflammatory fragment of a stress hormone. Here is what the current evidence shows, where it falls short, and what honest expectations look like.
Peptides can interact with prescription medications in ways that affect safety and efficacy. This guide covers the most clinically significant interactions — GLP-1 drugs with diabetes and blood pressure medications, GH secretagogues with corticosteroids and insulin, PT-141 with antihypertensives, and the universal rule about disclosing peptide use to all providers.
Thymosin alpha-1 is a 28-amino acid peptide from the thymus gland, approved for clinical use in over 35 countries and studied in viral hepatitis, cancer, sepsis, and immune deficiency. Here is what the evidence shows — and what patients considering it need to know.
Collagen peptides are the most widely consumed peptide supplement in the world. This guide covers the absorption mechanism, what peer-reviewed research shows for skin elasticity, joint health, bone density, and exercise recovery, how to evaluate products, and where the evidence is stronger or weaker than marketing suggests.
Epithalon (Epitalon) is a synthetic tetrapeptide developed in Russia with a proposed mechanism of telomere lengthening via telomerase activation. This guide examines the complete evidence base — the pineal biology origin, what telomere research actually shows, the Khavinson longevity studies, the cancer risk question, how epithalon compares to TA-65, and what patients need to know.
Kisspeptin is the upstream gatekeeper of the reproductive hormone axis. Here is what it is, what happens when it goes quiet (hypothalamic amenorrhoea, functional hypogonadism), what a landmark 2025 nasal spray trial found, and what patients need to know.
Selank and Semax are the two most studied Russian nootropic peptides. Both have real clinical evidence behind them — mostly from Russia. Here's what the research shows, how they compare, and what Western patients need to understand before seeking them out.
Tesamorelin (Egrifta) is the only GHRH analogue with FDA approval — for visceral fat reduction in HIV-associated lipodystrophy. Its emerging role in cognitive preservation and GLP-1 muscle-loss prevention makes it one of the most clinically interesting peptides in development.
Semaglutide and tirzepatide work — but the first weeks involve a learning curve most patients aren't prepared for. Here's a week-by-week guide to side effects, dosing, realistic expectations, injection technique, and when to call your provider.
Most peptides are shipped as lyophilized (freeze-dried) powder requiring reconstitution before use. This comprehensive guide covers why lyophilization is used, choosing the right diluent, concentration calculations, step-by-step reconstitution, storage conditions, compound-specific notes, travel logistics, needle disposal, and how to recognize compromised vials.
Sermorelin has a longer clinical history than any other growth hormone-releasing peptide — including an FDA approval that lasted over a decade. This guide covers its mechanism, the somatopause biology it targets, the adult evidence base, how it preserves pituitary feedback that exogenous HGH bypasses, dosing and monitoring, and how it compares to ipamorelin/CJC-1295 and tesamorelin.
Ipamorelin and CJC-1295 are among the most commonly prescribed peptides at longevity and anti-aging clinics. Here's what the research shows, how they differ from synthetic HGH, and what patients need to understand before starting.
PT-141, sold as Vyleesi, is one of the few peptides with FDA approval — for hypoactive sexual desire disorder in premenopausal women. Here's what patients should know about its mechanism, evidence, clinical use, and the off-label use landscape.
TB-500 is one of the most discussed research peptides for injury recovery. Here's a science-first look at what the actin biology, animal studies, and early human trials show — and what remains unproven about systemic use.
A complete breakdown of peptide compounding status in 2026 — Category 1, 2, and 3 classifications, 503A vs. 503B framework, GLP-1 case study, and compliance marketing guidance.
FDA regulation of peptides spans drug approval, compounding pharmacy rules, dietary supplement oversight, and enforcement against gray-market vendors. This guide explains the regulatory frameworks, how the Category 1/2 compounding lists work, the GLP-1 shortage episode, and how to verify the legal status of any compound.
BPC-157 (Body Protection Compound-157) is a synthetic peptide derived from human gastric protein with decades of animal research in tissue repair, gut health, and neuroscience. This guide covers the mechanisms, the evidence, why human trials haven't happened, and what the current regulatory status means for patients.
Peptides are increasingly marketed for anti-aging purposes. This article examines the evidence base category by category — from collagen peptides to GH secretagogues, GHK-Cu, epithalon, thymosin alpha-1, and MOTS-c — covering mechanisms, what human trials show, and where the evidence ends and extrapolation begins.
BPC-157 has become one of the most discussed research peptides in sports medicine and recovery contexts. This guide examines the complete preclinical evidence base — mechanisms, injury-type specific data, dose-response findings, and the critical limits of animal-to-human translation — so readers can assess the science accurately.
Before starting any peptide protocol, understanding the safety landscape is essential. This guide covers what is known — and unknown — about peptide safety, the risks of unsupervised use, specific contraindications, monitoring requirements, and how to minimize harm across each major peptide category.
With peptide therapy clinics proliferating online and in-person, knowing what to look for — and what red flags to avoid — is essential. This guide walks you through credentials, pharmacy vetting, protocol-specific questions, and the intake process benchmarks that separate quality providers from the rest.
GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have transformed diabetes and weight management. This guide explains how they work at the receptor level, what the clinical data shows, how they differ, and what patients need to understand before starting.
Peptides are short chains of amino acids found naturally in your body that regulate everything from metabolism to immunity. This beginner's guide explains what peptides are, how they work, the major categories used in health research, how to evaluate the evidence, and how to navigate the regulatory landscape before exploring peptide-based therapies.
No articles found for this tag.
Our news section covers the latest regulatory updates, clinical trial results, and peptide research developments.
Peptide Research Agent
Ask anything about peptides
Research info only — not medical advice.
